Grizzlyrock Capital LLC Acquires New Shares in Grifols, S.A. $GRFS

Grizzlyrock Capital LLC bought a new stake in Grifols, S.A. (NASDAQ:GRFS) during the second quarter, HoldingsChannel.com reports. The firm bought 166,000 shares of the biotechnology company’s stock, valued at approximately $1,501,000. Grifols comprises about 1.0% of Grizzlyrock Capital LLC’s investment portfolio, making the stock its 18th largest position.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Grifols by 2.4% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock valued at $427,000 after purchasing an additional 1,114 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Grifols by 4.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 62,991 shares of the biotechnology company’s stock valued at $569,000 after purchasing an additional 2,928 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 4,604 shares during the last quarter. Cetera Investment Advisers boosted its position in Grifols by 16.1% in the first quarter. Cetera Investment Advisers now owns 35,254 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 4,900 shares in the last quarter. Finally, Ballentine Partners LLC grew its stake in shares of Grifols by 48.9% during the second quarter. Ballentine Partners LLC now owns 16,179 shares of the biotechnology company’s stock worth $146,000 after buying an additional 5,311 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GRFS. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Zacks Research cut Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th. JPMorgan Chase & Co. cut their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.00.

Grifols Stock Performance

NASDAQ GRFS opened at $9.14 on Friday. The company has a market capitalization of $6.28 billion, a price-to-earnings ratio of 48.11, a PEG ratio of 0.38 and a beta of 0.67. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. Grifols, S.A. has a twelve month low of $6.19 and a twelve month high of $11.14. The stock has a fifty day simple moving average of $9.04 and a 200 day simple moving average of $9.43.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.